Skip Nav Destination
Issues
15 January 2011
-
Cover Image
Cover Image
Immunofluorescence analysis demonstrating the cytoplasmic localization of galectin-3 in CD18/HPAF pancreatic cancer cells transfected with scramble control vector. The cells were grown at low density on sterile cover slips for 20 hours. After washing with 0.1 M HEPES-containing Hanks buffer, the cells were fixed in ice-cold methanol at −20°C for 2 minutes. After nonspecific blocking with 10% goat serum, cells were incubated with antigalectin-3 antibody in PBS for 90 minutes at room temperature. Cells were washed 3 to 4 times with PBS containing 0.05% Tween-20 (PBS-T) and then incubated with FITC-conjugated anti-rat secondary antibodies for 60 minutes. The cells were counterstained with propidium iodide. Finally, slides were washed, mounted, and observed under a ZEISS confocal laser-scanning microscope. Photographs were digitally captured by using 510-software. For further details, please see Senapati and coworkers on page 267 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
Molecular Pathways
Review
Decreasing the Adverse Effects of Cancer Therapy: National Cancer Institute Guidance for the Clinical Development of Radiation Injury Mitigators
Benjamin Movsas; Bhadrasain Vikram; Martin Hauer-Jensen; John E. Moulder; Ethan Basch; Stephen L. Brown; Lisa A. Kachnic; Adam P. Dicker; C. Norman Coleman; Paul Okunieff
Human Cancer Biology
Extent and Patterns of MGMT Promoter Methylation in Glioblastoma- and Respective Glioblastoma-Derived Spheres
Davide Sciuscio; Annie-Claire Diserens; Kristof van Dommelen; Danielle Martinet; Greg Jones; Robert-Charles Janzer; Claudio Pollo; Marie-France Hamou; Bernd Kaina; Roger Stupp; Marc Levivier; Monika E. Hegi
Cancer Therapy: Preclinical
Modulating Endogenous NQO1 Levels Identifies Key Regulatory Mechanisms of Action of β-Lapachone for Pancreatic Cancer Therapy
Long Shan Li; Erik A. Bey; Ying Dong; Jieru Meng; Biswanath Patra; Jingsheng Yan; Xian-Jin Xie; Rolf A. Brekken; Carlton C. Barnett; William G. Bornmann; Jinming Gao; David A. Boothman
Imaging, Diagnosis, Prognosis
β-Catenin Activation Is Associated with Specific Clinical and Pathologic Characteristics and a Poor Outcome in Adrenocortical Carcinoma
Sébastien Gaujoux; Sophie Grabar; Martin Fassnacht; Bruno Ragazzon; Pierre Launay; Rossella Libé; Ilham Chokri; Anne Audebourg; Benedict Royer; Silviu Sbiera; Marie-Cécile Vacher-Lavenu; Bertrand Dousset; Xavier Bertagna; Bruno Allolio; Jérôme Bertherat; Frédérique Tissier
Cancer Therapy: Clinical
Primary CNS Lymphoma in Children and Adolescents: A Descriptive Analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG)
Oussama Abla; Sheila Weitzman; Jean-Yves Blay; Brian Patrick O'Neill; Lauren E. Abrey; Edward Neuwelt; Nancy D. Doolittle; Joachim Baehring; Kamnesh Pradhan; S. Eric Martin; Michael Guerrera; Shafqat Shah; Hervé Ghesquieres; Michael Silver; Rebecca A. Betensky; Tracy Batchelor
Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin
Anthony W. Tolcher; Christopher J. Sweeney; Kyri Papadopoulos; Amita Patnaik; Elena G. Chiorean; Alain C. Mita; Kamalesh Sankhala; Eric Furfine; Jochem Gokemeijer; Lisa Iacono; Cheryl Eaton; Bruce A. Silver; Monica Mita
Predictive Biomarkers and Personalized Medicine
Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer
Adrian M. Jubb; Kathy D. Miller; Hope S. Rugo; Adrian L. Harris; Dafeng Chen; James D. Reimann; Melody A. Cobleigh; Maike Schmidt; Virginia K. Langmuir; Kenneth J. Hillan; Daniel S. Chen; Hartmut Koeppen
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.